Reduction of infracardiac intestinal activity by a small amount of soda water in technetium-99m tetrofosmin myocardial perfusion scintigraphy with adenosine stress.
BACKGROUND
In technetium (Tc)-99m myocardial perfusion imaging (MPI), intestinal activity often interferes with the assessment of myocardial perfusion of the inferior wall. We examined whether a small amount of soda water prevents intestinal activity and improves image quality of the inferior wall in Tc-99m tetrofosmin MPI.


RESULTS
Ninety-five patients referred for 1-day rest/stress Tc-99m tetrofosmin MPI were assigned to one of two groups automatically, according to the date when they underwent MPI: the soda water group (n = 63) ingested 100 mL soda water just before image acquisition after adenosine stress, and the control group (n = 32) underwent no intervention. The frequency of intestinal activity was assessed visually on planar images. The inferior myocardial wall and the abdominal activity adjacent to the myocardium were assessed quantitatively on three different planar images during stress, and the mean inferior wall-to-abdomen (I/A) count ratio was calculated. The frequency of intestinal activity was 69.8% in the soda water group, and 90.6% in the control group (P = .038). The I/A count ratio was significantly higher in the soda water group than in the control group (1.98 +/- 0.51 vs 1.50 +/- 0.35, respectively, P < .0001, +/- SD).


CONCLUSIONS
The intake of 100 mL of soda water improves intestinal activity and improves the image quality of the inferior wall.
Hara
Masatake
M
Department of Cardiology, Otsu Red Cross Hospital, Otsu City, Shiga, Japan. har@otsu.jrc.or.jp
Monzen
Hajime
H
Futai
Rie
R
Inagaki
Koichi
K
Shimoyama
Hisashi
H
Morikawa
Masaru
M
Tomioka
Nobuyoshi
N
Konishi
Takashi
T
Watanabe
Yutaka
Y
Yuki
Rumio
R
Kobayashi
Hisato
H
Hirose
Kunihiko
K
D000241:Adenosine / Q000008:administration & dosage; D000368:Aged; D016477:Artifacts; D002253:Carbonated Beverages; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000000981:diagnostic imaging* / Q000187:drug effects; D008297:Male; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics*; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000378:metabolism*
D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C078700:technetium tc-99m tetrofosmin; D000241:Adenosine